

Clinical Trial Operations Platform - ClinOps

Design Thinking & Innovation Strategy

Team 1:

- Mohit Barade
- Anupama Singh
- Pranav Trivedi
- Yashashav Devalapalli Kamalraj

Three-Phase Design Approach: EMPATHIZE -> DEFINE -> IDEATE

PHASE 1: EMPATHIZE

Goal: Understand the users and context deeply.

Deliverables

- User research plan (who, how, what you'll study)
- Interview transcripts & observation notes
- Empathy maps / journey maps
- Key insights (quotes, pain points, opportunities)

USER RESEARCH PLAN

Who We Studied

User Group	Role
Trial Coordinator / Site Managers	Primary day-to-day planners
Regulatory & QA Advisors / CRAs	Compliance gatekeepers
Sponsor Project Managers	Multi-site overseers

Research Methodology

- 3 remote sessions (30-45 min) via Zoom with screen-shares
- Semi-structured interviews using 10 discovery questions
- Task walk-throughs: Trial Overview, Task Checklists, Timeline, Document Control, Audit Prep, Smart Alerts

- Artifact reviews of binders, Excel checklists, version trackers, email templates

What We Studied

- Protocol -> timeline translation and site wave planning
- Audit-binder assembly and readiness
- Document version/expiry handling (ICF, lab manuals, approvals)
- How alerts/checklists guide activities across phases

KEY FINDINGS FROM INTERVIEWS

User Quotes (Pain Points)

- I spend a day just syncing Gantt timelines with protocol updates.
- Version control across countries is a nightmare - every email has a different form.
- Audit prep eats up a whole week when templates aren't ready.
- I'd love if something just told me what's about to expire before QA does.
- Manual timelines slip across site waves.
- Version drift (ICF, lab manuals) becomes findings.
- Audit folders take days without a template.

Key Observations

- Coordinators copy protocol milestones into Excel; dependencies are easy to miss
- Regulatory tracks expirations with color-coded spreadsheets
- Binders maintained both digitally and on paper for audits
- Teams switch between CTMS, SharePoint, and email - causes version drift
- Time sinks: manual Gantt updates; binder assembly; reconciling versions

EMPATHY MAPS

Trial Coordinator - Rina

Says	I just want my site to activate on time.
Thinks	Dependencies are invisible when everything's manual.
Does	Builds timelines in Excel; emails updates; tracks enrollment
Feels	Frustrated; rushed before activation
Motivation	Reduce manual rework and activate sites on time

Regulatory Advisor - Omar

Says	One wrong version can cause a finding.
Thinks	If I could see expirations in one place, I'd sleep better.
Does	Reviews trackers; compares dates; preps for audits
Feels	Cautious; detail-oriented; occasionally overwhelmed
Motivation	Achieve zero findings with centralized version tracking

JOURNEY MAP

Phase	Actions	Emotions	Blockers
Pre-Study	Read protocol; set milestones	Curious / Optimistic	Hard to estimate durations
Site Initiation	Build Gantt; assign tasks	Overwhelmed	Manual re-entry of data
Enrollment	Monitor progress	Alert / Pressured	No unified tracker
Follow-up	Check expirations	Tense	No automatic alerts
Close-out	Assemble audit binder	Exhausted	Missing templates

PAIN POINTS & OPPORTUNITIES

Critical Pain Points

- Manual Gantt management and rework after amendments
- No cross-system synchronization; version drift across email
- Time-intensive binder assembly; high risk of missed expirations

Strategic Opportunities

- Automate protocol-to-timeline generation with built-in dependencies
- Provide pre-built audit templates and readiness checklists
- Centralize version/expiry status with proactive alerts

PHASE 2: DEFINE

Goal: Synthesize insights into a clear, actionable problem statement.

Deliverables

- Point of View (POV) statements
- How Might We (HMW) questions to frame ideation
- Problem framing document with storyboard
- Refined user personas

POINT OF VIEW (POV) STATEMENTS

Trial Coordinator: A coordinator at a multi-site study needs a fast way to turn protocol + site waves into an actionable plan because manual timelines hide dependencies and delay activation.

Regulatory Advisor: A QA/RA lead needs clear visibility of document versions/expirations because small mismatches trigger avoidable findings.

HOW MIGHT WE (HMW) QUESTIONS

Framing challenges to drive ideation across prototype tabs:

Feature Area	HMW Question
Trial Timeline	How might we turn discovery answers into a draft timeline with dependencies?
Audit Preparation	How might we auto-outline audit folders and highlight missing items?
Document Control	How might we surface version/expiry status for critical docs?
Risk & Controls	How might we catalog risks and suggest prevention/remediation?
Smart Alerts	How might we flag potential compliance gaps from user-provided dates?

USER PERSONAS

Rina - Trial Coordinator

Goal	Activate sites on time; reduce manual rework
Frustration	Hidden dependencies; messy timelines that break after amendments
Key Quote	I'm always fixing Ganttts after protocol amendments.
Need	Translate protocol into actionable site plans with minimal re-entry
Environment	Excel + CTMS + Teams; hybrid work
Success Metric	Timeline generation < 2 hours; 0 missed milestones

Omar - Regulatory Advisor

Goal	Achieve zero findings during audits
Frustration	Lost versions; expiring certificates; disparate tracking
Key Quote	Half my stress is keeping versions straight.
Need	Centralized expiry/version tracker with proactive guidance
Environment	Remote QA team; shared drives and email
Success Metric	Zero version-related findings; 100% readiness

Priya - Sponsor PM

Goal	Cross-site consistency and transparency
Frustration	Disparate progress; unclear readiness status across sites
Key Quote	I can't tell which sites are really audit-ready.
Need	At-a-glance dashboards and automated risk alerts
Environment	Multi-site oversight; monthly reporting cadence
Success Metric	Real-time dashboard; proactive alerts

PHASE 3: IDEATE

Goal: Generate a wide range of creative solutions.

Deliverables

- Brainstorming outputs and feature concept sketches
- Concept prioritization matrix (feasibility vs impact)
- Top concept cards and storyboards for validation

BRAINSTORMING: CORE FEATURE CONCEPTS

Feature Concept	Description
Instant Timeline	Draft Gantt from protocol + site waves with dependencies
Audit-Readiness Kit	Folder tree + readiness checklist; authority-aware templates
Compliance Guardrails	Version/expiry checks and signature tracking
Risk & Controls Matrix	Catalog of risks with prevention/remediation strategies
Smart Alerts	In-chat flags for expiries, mismatches, and trends
Workflow/Compliance Diagrams	Visual flows: Enrollment, AE/SAE, monitoring, data queries

PRIORITIZATION MATRIX: FEASIBILITY vs IMPACT

Strategic prioritization for phased rollout:

Feature	Feasibility	Impact	Phase
Instant Timeline	High	High	NOW - Phase 1
Audit Binder Generator	High	High	NOW - Phase 1
Compliance Guardrails	High	High	NOW - Phase 1
Smart Alerts	High	High	NOW - Phase 2
Workflow/Compliance Diagrams	High	High	NOW - Phase 2
Integrated Background Alerts	Medium	High	FUTURE - Phase 3
Real-time CTMS/eTMF Sync	Low	High	FUTURE - Phase 3

TOP 3 CONCEPT CARDS

1. INSTANT TIMELINE

Problem	Manual protocol timelines are slow, error-prone, and miss dependencies
Solution	AI converts protocol + site waves into a Gantt plan with automatic dependency mapping
Value Proposition	Saves 8-12 hours per trial; reduces missed milestones by 90%
Target User	Trial Coordinator (Rina)
Success Metrics	Timeline generated in <30 min with actionable tasks

2. AUDIT-READINESS KIT

Problem	Binder creation is tedious, inconsistent, and takes days to assemble
Solution	Authority-aware folder structure + readiness checklist + gap-finder
Value Proposition	Inspection-ready binder in hours, not days; reduced findings
Target User	Regulatory Advisor (Omar)
Success Metrics	100% checklist coverage; zero missing documents at audit

3. COMPLIANCE GUARDRAILS

Problem	Expiring documents and mismatched versions create avoidable findings
Solution	Users input key doc dates/versions; AI flags risks and recommends actions
Value Proposition	Prevents findings; boosts team confidence pre-audit
Target User	QA/RA Leads (Omar, Priya)
Success Metrics	Proactive alerts 30 days before expiry; 0 version-related findings

STORYBOARD: INSTANT TIMELINE (4-Panel Narrative)

Panel 1: Discovery

Rina opens the platform and uploads protocol document. A blank timeline stares back, daunting.

Panel 2: Generation

She submits 10 quick discovery answers about site waves, key milestones, and dependencies. AI drafts a structured timeline in seconds.

Panel 3: Refinement

Dependencies and tasks auto-populate. She adjusts dates in chat, moves milestones, and tags responsible teams.

Panel 4: Delight

Rina smiles. Finally, a head start! She exports and shares the Gantt with the team - no manual re-entry needed.

CONSTRAINTS & SCOPE GUARDRAILS (v1)

- Outputs are generated in chat (text/tables/diagram definitions only)
- No external EDC/CTMS/eTMF integrations or background jobs
- Smart Alerts are generated on-demand from user-entered data (not real-time)
- Document Control reflects user-provided versions/expirations (no auto-sync)
- PHI is NOT collected or stored in platform

REFERENCES

- “Title 21 CFR Part 11,” Wikipedia. [Online]. Available: https://en.wikipedia.org/wiki/Title_21_CFR_Part_11.
- U.S. Food and Drug Administration, “Regulations: Good Clinical Practice and Clinical Trials.” [Online]. Available: <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/regulations-good-clinical-practice-and-clinical-trials>.
- “European Union Clinical Trials Regulation,” Wikipedia. [Online]. Available: https://en.wikipedia.org/wiki/European_Union_Clinical_Trials_Regulation.
- International Council for Harmonisation, “ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2),” 2016. [Online]. Available: https://admin.ich.org/sites/default/files/inline-files/E6_R2_Addendum_Step2.pdf.
- C. B. Simone II et al., “Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PD-L1–Unselected Stage III Non-Small Cell Lung Cancer: Brief Report,” PubMed, 2024. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/39147210/>.
- A. T. Shaw, T. M. Bauer, F. de Marinis et al., “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer,” New England Journal of Medicine, vol. 383, no. 21, pp. 2018–2029, 2020. [Online]. Available: <https://www.nejm.org/doi/full/10.1056/NEJMoa2027187>.